{"id":4027,"date":"2022-10-19T08:46:26","date_gmt":"2022-10-19T08:46:26","guid":{"rendered":"https:\/\/fundaciomiquelvalls.org\/?p=4027"},"modified":"2022-10-19T08:54:48","modified_gmt":"2022-10-19T08:54:48","slug":"fda-aprueba-medicamento-relyvrio","status":"publish","type":"post","link":"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/","title":{"rendered":"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">La compa\u00f1\u00eda AMYLIX PHARMACEUTICALS, INC. anunci\u00f3 el pasado 29 de septiembre la aprobaci\u00f3n del medicamento RELYVRIO para el tratamiento de la ELA, por parte de la Food and Drug Administration (FDA) de los Estados Unidos de Am\u00e9rica.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La aprobaci\u00f3n se llev\u00f3 a cabo atendiendo a los resultados del ensayo cl\u00ednico Centaur, que mostr\u00f3 una reducci\u00f3n significativa de la p\u00e9rdida de la funci\u00f3n f\u00edsica en pacientes con ELA.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El diario estadounidense New York Times recoge testimonios de distintos profesionales y asociaciones de pacientes de ELA que ayudan a entender la importancia que ha tenido este proceso en Estados Unidos.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Para m\u00e1s informaci\u00f3n, a continuaci\u00f3n os dejamos el art\u00edculo que ha publicado el Aula ELA-Bellvitge Pacientes al respecto:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/ca\/el-new-york-times-explica-laprovacio-del-relyvrio-als-estats-units-per-al-tractament-de-lela\/\" target=\"_blank\" rel=\"noreferrer noopener\">http:\/\/blogs.bellvitgehospital.cat\/aulaela\/ca\/el-new-york-times-explica-laprovacio-del-relyvrio-als-estats-units-per-al-tractament-de-lela\/<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Y tambi\u00e9n le dejamos el enlace al art\u00edculo entero del New York Times:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.nytimes.com\/2022\/09\/29\/health\/als-treatment-relyvrio.html\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.nytimes.com\/2022\/09\/29\/health\/als-treatment-relyvrio.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La compa\u00f1\u00eda AMYLIX PHARMACEUTICALS, INC. anunci\u00f3 el pasado 29 de septiembre la aprobaci\u00f3n del medicamento RELYVRIO para el tratamiento de la ELA, por parte de la Food and Drug Administration (FDA) de los Estados Unidos de Am\u00e9rica. La aprobaci\u00f3n se llev\u00f3 a cabo atendiendo a los resultados del ensayo cl\u00ednico Centaur, que mostr\u00f3 una reducci\u00f3n significativa de la p\u00e9rdida de la funci\u00f3n f\u00edsica en pacientes con ELA. El diario estadounidense New York Times recoge testimonios de distintos profesionales y asociaciones de pacientes de ELA que ayudan a entender la importancia que ha tenido este proceso en Estados Unidos. Para m\u00e1s informaci\u00f3n, a continuaci\u00f3n os dejamos el art\u00edculo que ha publicado el Aula ELA-Bellvitge Pacientes al respecto: http:\/\/blogs.bellvitgehospital.cat\/aulaela\/ca\/el-new-york-times-explica-laprovacio-del-relyvrio-als-estats-units-per-al-tractament-de-lela\/ Y tambi\u00e9n le dejamos el enlace al art\u00edculo entero del New York Times: https:\/\/www.nytimes.com\/2022\/09\/29\/health\/als-treatment-relyvrio.html<\/p>\n","protected":false},"author":1,"featured_media":4028,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[91,122,188,193],"class_list":["post-4027","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualitat-es","tag-ela-es","tag-fundacio-catalana-dela-miquel-valls-es","tag-relyvrio","tag-tratamiento-2"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA - Fundaci\u00f3 Catalana d&#039;ELA Miquel Valls<\/title>\n<meta name=\"description\" content=\"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA\" \/>\n<meta property=\"og:description\" content=\"La compa\u00f1\u00eda AMYLIX PHARMACEUTICALS, INC. anunci\u00f3 el pasado 29 de septiembre la aprobaci\u00f3n del medicamento RELYVRIO para el tratamiento de la ELA, por parte de la Food and Drug Administration (FDA) de los Estados Unidos de Am\u00e9rica.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/\" \/>\n<meta property=\"og:site_name\" content=\"Fundaci\u00f3 Catalana d&#039;ELA Miquel Valls\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-19T08:46:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-19T08:54:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fundaciomiquelvalls.org\/wp-content\/uploads\/2022\/10\/ap21113587396498_wide-1ce44202a52d21d0ee24cfd9634baffbabe1c51f-s1400-c100.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1400\" \/>\n\t<meta property=\"og:image:height\" content=\"787\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fundaci\u00f3 Catalana d&#039;ELA Miquel Valls\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA\" \/>\n<meta name=\"twitter:description\" content=\"La compa\u00f1\u00eda AMYLIX PHARMACEUTICALS, INC. anunci\u00f3 el pasado 29 de septiembre la aprobaci\u00f3n del medicamento RELYVRIO para el tratamiento de la ELA, por parte de la Food and Drug Administration (FDA) de los Estados Unidos de Am\u00e9rica.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/fundaciomiquelvalls.org\/wp-content\/uploads\/2022\/10\/ap21113587396498_wide-1ce44202a52d21d0ee24cfd9634baffbabe1c51f-s1400-c100.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fundaci\u00f3 Catalana d&#039;ELA Miquel Valls\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/\"},\"author\":{\"name\":\"Fundaci\u00f3 Catalana d'ELA Miquel Valls\",\"@id\":\"https:\/\/fundaciomiquelvalls.org\/#\/schema\/person\/49e4b390c29b931f8b4213fbd9276ea3\"},\"headline\":\"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA\",\"datePublished\":\"2022-10-19T08:46:26+00:00\",\"dateModified\":\"2022-10-19T08:54:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/\"},\"wordCount\":172,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fundaciomiquelvalls.org\/wp-content\/uploads\/2022\/10\/ap21113587396498_wide-1ce44202a52d21d0ee24cfd9634baffbabe1c51f-s1400-c100.jpg\",\"keywords\":[\"ELA\",\"Fundaci\u00f3 Catalana d&#039;ELA Miquel Valls\",\"Relyvrio\",\"Tratamiento\"],\"articleSection\":[\"Actualitat\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/\",\"url\":\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/\",\"name\":\"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA - Fundaci\u00f3 Catalana d&#039;ELA Miquel Valls\",\"isPartOf\":{\"@id\":\"https:\/\/fundaciomiquelvalls.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fundaciomiquelvalls.org\/wp-content\/uploads\/2022\/10\/ap21113587396498_wide-1ce44202a52d21d0ee24cfd9634baffbabe1c51f-s1400-c100.jpg\",\"datePublished\":\"2022-10-19T08:46:26+00:00\",\"dateModified\":\"2022-10-19T08:54:48+00:00\",\"author\":{\"@id\":\"https:\/\/fundaciomiquelvalls.org\/#\/schema\/person\/49e4b390c29b931f8b4213fbd9276ea3\"},\"description\":\"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA\",\"breadcrumb\":{\"@id\":\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/#primaryimage\",\"url\":\"https:\/\/fundaciomiquelvalls.org\/wp-content\/uploads\/2022\/10\/ap21113587396498_wide-1ce44202a52d21d0ee24cfd9634baffbabe1c51f-s1400-c100.jpg\",\"contentUrl\":\"https:\/\/fundaciomiquelvalls.org\/wp-content\/uploads\/2022\/10\/ap21113587396498_wide-1ce44202a52d21d0ee24cfd9634baffbabe1c51f-s1400-c100.jpg\",\"width\":1400,\"height\":787,\"caption\":\"FILE - This Dec. 10, 2020 file photo shows Food and Drug Administration building in Silver Spring, Md. Each year the U.S. approves dozens of new uses for cancer drugs based on early signs that they can shrink or slow the spread of tumors. But how often do patients actually live longer, more active lives? That seemingly simple question is, in fact, one of the thorniest debates in medicine. (AP Photo\/Manuel Balce Ceneta)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/fundaciomiquelvalls.org\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fundaciomiquelvalls.org\/#website\",\"url\":\"https:\/\/fundaciomiquelvalls.org\/\",\"name\":\"Fundaci\u00f3 Catalana d&#039;ELA Miquel Valls\",\"description\":\"Treballem per millorar la qualitat de vida de les persones afectades d&#039;ELA i Malaltia de Motoneurona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fundaciomiquelvalls.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/fundaciomiquelvalls.org\/#\/schema\/person\/49e4b390c29b931f8b4213fbd9276ea3\",\"name\":\"Fundaci\u00f3 Catalana d'ELA Miquel Valls\",\"sameAs\":[\"https:\/\/fundaciomiquelvalls.org\"],\"url\":\"https:\/\/fundaciomiquelvalls.org\/es\/author\/alojapro_dev\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA - Fundaci\u00f3 Catalana d&#039;ELA Miquel Valls","description":"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/","og_locale":"es_ES","og_type":"article","og_title":"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA","og_description":"La compa\u00f1\u00eda AMYLIX PHARMACEUTICALS, INC. anunci\u00f3 el pasado 29 de septiembre la aprobaci\u00f3n del medicamento RELYVRIO para el tratamiento de la ELA, por parte de la Food and Drug Administration (FDA) de los Estados Unidos de Am\u00e9rica.","og_url":"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/","og_site_name":"Fundaci\u00f3 Catalana d&#039;ELA Miquel Valls","article_published_time":"2022-10-19T08:46:26+00:00","article_modified_time":"2022-10-19T08:54:48+00:00","og_image":[{"width":1400,"height":787,"url":"https:\/\/fundaciomiquelvalls.org\/wp-content\/uploads\/2022\/10\/ap21113587396498_wide-1ce44202a52d21d0ee24cfd9634baffbabe1c51f-s1400-c100.jpg","type":"image\/jpeg"}],"author":"Fundaci\u00f3 Catalana d'ELA Miquel Valls","twitter_card":"summary_large_image","twitter_title":"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA","twitter_description":"La compa\u00f1\u00eda AMYLIX PHARMACEUTICALS, INC. anunci\u00f3 el pasado 29 de septiembre la aprobaci\u00f3n del medicamento RELYVRIO para el tratamiento de la ELA, por parte de la Food and Drug Administration (FDA) de los Estados Unidos de Am\u00e9rica.","twitter_image":"https:\/\/fundaciomiquelvalls.org\/wp-content\/uploads\/2022\/10\/ap21113587396498_wide-1ce44202a52d21d0ee24cfd9634baffbabe1c51f-s1400-c100.jpg","twitter_misc":{"Escrito por":"Fundaci\u00f3 Catalana d'ELA Miquel Valls","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/#article","isPartOf":{"@id":"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/"},"author":{"name":"Fundaci\u00f3 Catalana d'ELA Miquel Valls","@id":"https:\/\/fundaciomiquelvalls.org\/#\/schema\/person\/49e4b390c29b931f8b4213fbd9276ea3"},"headline":"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA","datePublished":"2022-10-19T08:46:26+00:00","dateModified":"2022-10-19T08:54:48+00:00","mainEntityOfPage":{"@id":"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/"},"wordCount":172,"commentCount":0,"image":{"@id":"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/#primaryimage"},"thumbnailUrl":"https:\/\/fundaciomiquelvalls.org\/wp-content\/uploads\/2022\/10\/ap21113587396498_wide-1ce44202a52d21d0ee24cfd9634baffbabe1c51f-s1400-c100.jpg","keywords":["ELA","Fundaci\u00f3 Catalana d&#039;ELA Miquel Valls","Relyvrio","Tratamiento"],"articleSection":["Actualitat"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/","url":"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/","name":"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA - Fundaci\u00f3 Catalana d&#039;ELA Miquel Valls","isPartOf":{"@id":"https:\/\/fundaciomiquelvalls.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/#primaryimage"},"image":{"@id":"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/#primaryimage"},"thumbnailUrl":"https:\/\/fundaciomiquelvalls.org\/wp-content\/uploads\/2022\/10\/ap21113587396498_wide-1ce44202a52d21d0ee24cfd9634baffbabe1c51f-s1400-c100.jpg","datePublished":"2022-10-19T08:46:26+00:00","dateModified":"2022-10-19T08:54:48+00:00","author":{"@id":"https:\/\/fundaciomiquelvalls.org\/#\/schema\/person\/49e4b390c29b931f8b4213fbd9276ea3"},"description":"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA","breadcrumb":{"@id":"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/#primaryimage","url":"https:\/\/fundaciomiquelvalls.org\/wp-content\/uploads\/2022\/10\/ap21113587396498_wide-1ce44202a52d21d0ee24cfd9634baffbabe1c51f-s1400-c100.jpg","contentUrl":"https:\/\/fundaciomiquelvalls.org\/wp-content\/uploads\/2022\/10\/ap21113587396498_wide-1ce44202a52d21d0ee24cfd9634baffbabe1c51f-s1400-c100.jpg","width":1400,"height":787,"caption":"FILE - This Dec. 10, 2020 file photo shows Food and Drug Administration building in Silver Spring, Md. Each year the U.S. approves dozens of new uses for cancer drugs based on early signs that they can shrink or slow the spread of tumors. But how often do patients actually live longer, more active lives? That seemingly simple question is, in fact, one of the thorniest debates in medicine. (AP Photo\/Manuel Balce Ceneta)"},{"@type":"BreadcrumbList","@id":"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fundaciomiquelvalls.org\/es\/"},{"@type":"ListItem","position":2,"name":"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA"}]},{"@type":"WebSite","@id":"https:\/\/fundaciomiquelvalls.org\/#website","url":"https:\/\/fundaciomiquelvalls.org\/","name":"Fundaci\u00f3 Catalana d&#039;ELA Miquel Valls","description":"Treballem per millorar la qualitat de vida de les persones afectades d&#039;ELA i Malaltia de Motoneurona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fundaciomiquelvalls.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/fundaciomiquelvalls.org\/#\/schema\/person\/49e4b390c29b931f8b4213fbd9276ea3","name":"Fundaci\u00f3 Catalana d'ELA Miquel Valls","sameAs":["https:\/\/fundaciomiquelvalls.org"],"url":"https:\/\/fundaciomiquelvalls.org\/es\/author\/alojapro_dev\/"}]}},"_links":{"self":[{"href":"https:\/\/fundaciomiquelvalls.org\/es\/wp-json\/wp\/v2\/posts\/4027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fundaciomiquelvalls.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fundaciomiquelvalls.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fundaciomiquelvalls.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fundaciomiquelvalls.org\/es\/wp-json\/wp\/v2\/comments?post=4027"}],"version-history":[{"count":3,"href":"https:\/\/fundaciomiquelvalls.org\/es\/wp-json\/wp\/v2\/posts\/4027\/revisions"}],"predecessor-version":[{"id":4037,"href":"https:\/\/fundaciomiquelvalls.org\/es\/wp-json\/wp\/v2\/posts\/4027\/revisions\/4037"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fundaciomiquelvalls.org\/es\/wp-json\/wp\/v2\/media\/4028"}],"wp:attachment":[{"href":"https:\/\/fundaciomiquelvalls.org\/es\/wp-json\/wp\/v2\/media?parent=4027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fundaciomiquelvalls.org\/es\/wp-json\/wp\/v2\/categories?post=4027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fundaciomiquelvalls.org\/es\/wp-json\/wp\/v2\/tags?post=4027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}